Table 1.
Characteristics of clinical trials and drugs on TAM-targeted therapy stratified by targeting mechanisms.
| Targeting pathways and mechanisms | Active drugs | Combination therapy | Cancer type | Phase | Clinical Trial ID |
|---|---|---|---|---|---|
| CSF-1/CSF-1R | ARRY-382 | Pembrolizumab | Advanced Solid Tumors | II | NCT02880371 |
| Pexidartinib | Durvalumab | Colorectal Cancer, Pancreatic Cancer | I | NCT02777710 | |
| CCL2/CCR2 | BMS-813160 | Nivolumab | Colorectal Cancer, Pancreatic Cancer | Ib/II | NCT03184870 |
| Non-small Cell Lung Cancer Hepatocellular Carcinoma |
II | NCT04123379 | |||
| Advanced Cancer | II | NCT02996110 | |||
| Pancreatic Ductal Adenocarcinoma | I/II |
NCT03767582 NCT03496662 |
|||
| CCL5/CCR5 | Maraviroc | Pembrolizumab | Metastatic Colorectal Cancer | I | NCT03274804 |
| Vicriviroc | Pembrolizumab | Colorectal Neoplasms | II | NCT03631407 | |
| CXCL12/CXCR4 | Motixafortide | Cemiplimab | Pancreatic Cancer | II | NCT04543071 |
| CD40/CD40L | ABBV-927 | Budigalimab | Pancreatic Cancer | II | NCT04807972 |
| Selicrelumab | Atezolizumab | Solid Tumors | I | NCT02304393 | |
| YH-003 | Toripalimab | Advanced Solid Tumors | I/II |
NCT04481009 NCT05031494 |
|
| Pembrolizumab | Solid Tumor | I | NCT05176509 | ||
| TLR7 | BDB-001 | Atezolizumab | Solid Tumor | I/II |
NCT03915678 NCT04196530 |
| Pembrolizumab | Solid Tumor | I |
NCT03486301 NCT04840394 |
||
| BDC-1001 | Nivolumab | HER2 Positive Solid Tumors | I/II | NCT04278144 | |
| DSP-0509 | Pembrolizumab | Neoplasms | I/II | NCT03416335 | |
| Resiquimod | Pembrolizumab | Advanced Solid Tumor Locally Advanced Solid Tumor Metastatic Solid Tumor |
I/II | NCT04799054 | |
| TLR8 | SBT6050 | Pembrolizumab | HER2 Positive Solid Tumors | I/Ib | NCT04460456 |
| Motolimod | Durvalumab | Ovarian Cancer | I/II | NCT02431559 | |
| TLR9 | CMP-001 | Atezolizumab | Non-Small Cell Lung Cancer | Ib | NCT03438318 |
| Nivolumab | Melanoma, Lymph Node Cancer | II/III |
NCT04695977 NCT04698187 NCT04401995 NCT03618641 |
||
| Pembrolizumab | Carcinoma, Squamous Cell of Head and Neck | II | NCT04633278 | ||
| Lymphoma | I/II | NCT03983668 | |||
| Melanoma | Ib/II |
NCT03084640 NCT02680184 NCT04708418 |
|||
| Tilsotolimod | Nivolumab | Advanced Cancer | I | NCT04270864 | |
| Solid Tumor | II | NCT03865082 | |||
| SD-101 | Nivolumab | Pancreatic Adenocarcinoma | I | NCT04050085 | |
| Metastatic Uveal Melanoma in the Liver | I/Ib | NCT04935229 | |||
| Pembrolizumab | Prostatic Neoplasms | II | NCT03007732 | ||
| Pembrolizumab Nivolumab |
Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma |
Ib/II | NCT05220722 | ||
| Cavrotolimod | Pembrolizumab Cemiplimab |
Advanced or Metastatic Solid Tumors | Ib/II | NCT03684785 | |
| TLR3 | Rintatolimod | Pembrolizumab | Ovarian Cancer Recurrent | I/II | NCT03734692 |
| PI3Kγ signal pathway | Copanlisib | Durvalumab | Non-Small Cell Lung Cancer | I | NCT04895579 |
| Nivolumab | Colon Cancer | I/II | NCT03711058 | ||
| Malignant Solid Neoplasm | I/II | NCT04317105 | |||
| Non-Small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma Hepatocellular Carcinoma |
Ib/II | NCT03735628 | |||
| Ann Arbor Stage III Lymphoma Ann Arbor Stage IV Lymphoma Solid Neoplasm |
Ib | NCT03502733 | |||
| Indolent Lymphoma | Ib | NCT04431635 | |||
| Lymphoma | I | NCT03884998 | |||
| Recurrent Diffuse Large B-Cell Lymphoma | II | NCT03484819 | |||
| Duvelisib | Nivolumab | Unresectable Melanoma | I/II | NCT04688658 | |
| Chronic Lymphocytic Leukemia Diffuse Large B-Cell Lymphoma |
I | NCT03892044 | |||
| CD47/SIRPα pathway | ALX-148 | Pembrolizumab | Microsatellite Stable Metastatic Colorectal Cancer | II | NCT05167409 |
| Solid Tumor, Non-Hodgkin Lymphoma | I | NCT03013218 | |||
| Head and Neck Cancer Head and Neck Squamous Cell Carcinoma |
II |
NCT04675294 NCT04675333 |
|||
| AO-176 | Pembrolizumab | Solid Tumor | I/II | NCT03834948 | |
| Magrolimab | Pembrolizumab | Head and Neck Squamous Cell Carcinoma | II | NCT04854499 | |
| Hodgkin Lymphoma | II | NCT04788043 | |||
| STING pathway | SNX-281 | Pembrolizumab | Advanced Solid Tumor Advanced Lymphoma |
I | NCT04609579 |
| BMS-986301 | Nivolumab | Advanced Solid Cancers | I | NCT03956680 | |
| SYNB-1891 | Atezolizumab | Metastatic Solid Neoplasm, Lymphoma | I | NCT04167137 | |
| TAK-676 | Pembrolizumab | Solid Neoplasms | I | NCT04420884 | |
| MK-2118 | Pembrolizumab | Solid Tumor, Lymphoma | I | NCT03249792 | |
| MK-1454 | Pembrolizumab | Solid Tumors, Lymphoma | I | NCT03010176 | |
| Head and Neck Squamous Cell Carcinoma | II | NCT04220866 | |||
| SB-11285 | Atezolizumab | Solid Tumor, Melanoma Head and Neck Squamous Cell Carcinoma |
Ia/Ib | NCT04096638 |